公开(公告)号：US20230038355A1

公开(公告)日：2023-02-09

申请号：US17860453

申请日：2022-07-08

Applicant: Janssen Biotech, Inc.

Inventor： Ann Donlon ,  Charles Goochee ,  Ronan Hayes ,  Robin Johnston ,  Willem Steenvoorden ,  Denis Twomey ,  Gary Gordon

IPC: C07K16/24 ,  C12P21/00 ,  C12N5/09

Abstract: The present disclosure relates to methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, and specific pharmaceutical compositions of the antibody.

公开(公告)号：US20230042465A1

公开(公告)日：2023-02-09

申请号：US17860416

申请日：2022-07-08

Applicant: Janssen Biotech, Inc.

Inventor： Ann Donlon ,  Charles Goochee ,  Gary Gordon ,  Ronan Hayes ,  Robin Johnston, JR. ,  Willem Steenvoorden ,  Denis Twomey

IPC: C07K16/24

Abstract: The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody golimumab, and specific pharmaceutical compositions of the antibody.

公开(公告)号：US20230040065A1

公开(公告)日：2023-02-09

申请号：US17860244

申请日：2022-07-08

Applicant: Janssen Biotech, Inc.

Inventor： Kristopher Barnthouse ,  John Brown ,  Brett Hanna ,  Linda Hendricks ,  Manuel Lopez, JR. ,  Mark Panek ,  Denis Twomey ,  David Volkin

IPC: C07K16/24

Abstract: The present invention relates to methods of manufacture for producing a drug substance (DS) or drug product (DP) comprising a mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO: 36 and a light chain (LC) comprising SEQ ID NO: 37.